Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Jagsonpal Pharma
Join Channel
Consolidated Standalone

Jagsonpal Pharma

₹318.5 -4.6 | 1.4%

Market Cap ₹842 Cr.

Stock P/E 31.3

P/B 4.7

Current Price ₹318.5

Book Value ₹ 67.7

Face Value 5

52W High ₹513.9

Dividend Yield 1.57%

52W Low ₹ 270.1

Edit Ratio

Jagsonpal Pharma Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Jagsonpal Pharmaceuticals Ltd is an primarily India-based pharmaceutical organization engaged in manufacturing of intermediate drugs and pharmaceuticals. The Company focuses on growing and production of bulk capsules and pharmaceutical formulations. It manufactures capsules, pills and ampoules. It operates R&D, manufacturing, marketing and distribution facilities. It develops and manufactures APIs and formulations. It gives products below diverse brands, together with Lycored, which includes lycopene with phytonutrients; Maintane, which includes allylestrenol; Metadec, which includes nandralone decanoate; Metabol, which includes nandralone phenyl propionate; Doxypal DR, which contains doxycycline delayed release; Parvon, and Indocap SR, which contains indomethacin sustained release. It has operations in Ukraine, Sri Lanka, Cameroon, Thailand, Russia, Brazil, the US, Argentina, Germany, Switzerland, Korea, Egypt and Vietnam.

Read More..

Jagsonpal Pharma Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Jagsonpal Pharma Quarterly Results

#(Fig in Cr.) Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Jun 2023 Sep 2023 Dec 2023
Net Sales 60 58 54 52 61 61 60 60 58 47
Other Income 1 0 2 0 0 1 2 2 2 3
Total Income 61 59 56 52 61 62 62 62 60 50
Total Expenditure 51 49 48 52 53 48 52 52 49 44
Operating Profit 10 10 8 1 7 14 10 11 11 6
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 1 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 -3 0 0 0 0 0
Profit Before Tax 10 9 7 0 4 14 10 10 10 5
Provision for Tax 3 3 2 0 1 3 2 3 2 1
Profit After Tax 7 7 5 0 3 10 8 7 7 4
Adjustments -0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 7 7 5 0 3 10 8 7 7 4
Adjusted Earnings Per Share 2.6 2.5 2 0 1.1 4 3 2.9 2.9 1.5

Jagsonpal Pharma Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 166 144 138 143 144 127 167 159 188 218 237 225
Other Income 0 0 0 1 0 0 1 3 4 3 6 9
Total Income 167 144 138 144 144 127 168 161 192 221 242 234
Total Expenditure 156 133 129 132 138 138 157 150 169 193 203 197
Operating Profit 10 11 9 12 6 -11 11 11 23 28 40 38
Interest 5 5 4 5 3 1 1 1 1 0 0 0
Depreciation 3 3 3 3 2 0 1 1 1 2 1 0
Exceptional Income / Expenses 0 0 0 0 13 0 0 0 0 0 -3 0
Profit Before Tax 3 3 2 4 14 -12 9 9 22 27 35 35
Provision for Tax 1 0 1 1 3 -0 2 2 5 8 8 8
Profit After Tax 2 2 1 3 12 -12 7 8 17 19 27 26
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 2 2 1 3 12 -12 7 8 17 19 27 26
Adjusted Earnings Per Share 0.7 0.8 0.4 1.2 4.5 -4.4 2.8 3 6.5 7.2 10.2 10.3

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 9% 14% 13% 4%
Operating Profit CAGR 43% 54% 0% 15%
PAT CAGR 42% 50% 0% 30%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -5% 47% 64% 36%
ROE Average 19% 17% 13% 7%
ROCE Average 24% 22% 17% 10%

Jagsonpal Pharma Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 98 99 95 98 110 98 104 111 122 133 159
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 4 4 4 4 3 3 3 3 2 4 8
Total Current Liabilities 50 54 55 57 29 29 28 35 40 34 35
Total Liabilities 153 156 154 159 143 130 136 149 164 171 203
Fixed Assets 58 56 52 52 22 21 22 24 26 23 24
Other Non-Current Assets 8 9 6 7 11 14 17 28 18 33 6
Total Current Assets 87 91 96 101 110 95 98 96 120 116 172
Total Assets 153 156 154 159 143 130 136 149 164 171 203

Jagsonpal Pharma Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 10 10 13 15 16 20 15 41 40 59 23
Cash Flow from Operating Activities 12 8 4 9 -3 -2 31 12 28 7 47
Cash Flow from Investing Activities -3 -1 -0 -2 41 -3 -1 -11 -2 -26 -58
Cash Flow from Financing Activities -8 -4 -1 -6 -34 -1 -6 -2 -7 -18 -0
Net Cash Inflow / Outflow 0 2 2 1 5 -6 24 -1 19 -36 -11
Closing Cash & Cash Equivalent 10 13 15 16 20 15 39 40 59 23 11

Jagsonpal Pharma Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0.7 0.81 0.45 1.24 4.53 -4.41 2.75 3 6.51 7.2 10.2
CEPS(Rs) 1.73 1.89 1.48 2.42 5.29 -4.29 3.14 3.44 6.93 7.78 10.66
DPS(Rs) 0.5 0.5 0.1 0.1 0.1 0.1 0.25 0.5 1 4 5
Book NAV/Share(Rs) 32.63 32.86 33.43 34.55 38.96 34.43 36.89 39.39 43.55 50.68 57.3
Core EBITDA Margin(%) 5.9 7.34 6.27 8.19 3.98 -8.77 5.6 5.38 10.15 10.32 13.28
EBIT Margin(%) 4.5 5.44 4.41 6.5 11.75 -8.66 5.84 6.26 11.91 11.11 13.7
Pre Tax Margin(%) 1.49 1.74 1.2 2.83 9.92 -9.18 5.4 5.94 11.64 10.99 13.54
PAT Margin (%) 1.08 1.46 0.84 2.26 8.18 -9.12 4.33 4.96 9.08 7.78 10.39
Cash Profit Margin (%) 2.66 3.4 2.79 4.4 9.55 -8.87 4.93 5.68 9.65 8.41 10.86
ROA(%) 1.19 1.37 0.75 2.08 7.86 -8.48 5.43 5.53 10.9 11.24 14.29
ROE(%) 2.15 2.47 1.35 3.65 12.32 -12.01 7.72 7.88 15.7 15.28 18.89
ROCE(%) 6.42 6.57 4.93 7.32 14.26 -10.52 9.8 9.46 19.43 21.23 24.15
Receivable days 90.52 109.72 118.23 109.58 102.03 93.07 50.22 48.57 33.13 21.26 25.87
Inventory Days 69.93 76.13 83.52 92.27 110.02 142.78 92.03 71.38 57.34 44.76 35.78
Payable days 20.72 20.12 26.19 43.17 49.18 53.98 52.49 76.56 67.24 75.08 68.44
PER(x) 14.45 12.65 63.76 26.36 8.41 0 9.55 5.81 12.22 43.57 28.42
Price/Book(x) 0.31 0.31 0.85 0.95 0.98 0.78 0.71 0.44 1.83 6.19 5.06
Dividend Yield(%) 4.95 4.88 0.35 0.31 0.26 0.37 0.95 2.87 1.26 1.28 1.72
EV/Net Sales(x) 0.3 0.35 0.72 0.76 0.61 0.51 0.2 0.07 0.82 3.66 2.72
EV/Core EBITDA(x) 4.77 4.67 11.2 8.72 14.06 -6.03 3.17 1.05 6.6 27.99 16.17
Net Sales Growth(%) -5.69 -13.58 -3.96 3.86 0.27 -12.05 31.84 -4.95 18.53 15.77 8.79
EBIT Growth(%) -46.92 3.17 -22.53 52.88 81.83 -164.37 188.87 1.85 125.46 20.29 30.8
PAT Growth(%) -75.42 15.72 -44.78 177.88 264.6 -197.35 162.47 9.07 116.73 10.53 41.72
EPS Growth(%) -75.42 15.72 -44.78 177.9 264.58 -197.35 162.47 9.08 116.73 10.53 41.72
Debt/Equity(x) 0.39 0.42 0.45 0.43 0.08 0.09 0.04 0.06 0.06 0 0
Current Ratio(x) 1.73 1.7 1.74 1.76 3.74 3.31 3.46 2.79 2.98 3.4 4.89
Quick Ratio(x) 1.13 1.13 1.14 1.07 2.12 1.51 2.3 1.94 2.25 2.53 4.31
Interest Cover(x) 1.49 1.47 1.37 1.77 6.44 -16.69 13.08 19.31 43.59 94.48 85.28
Total Debt/Mcap(x) 1.26 1.34 0.53 0.45 0.08 0.12 0.05 0.14 0.03 0 0

Jagsonpal Pharma Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 70.34 68.71 68.71 68.71 68.71 68.71 68.71 68.71 68.48 68.09
FII 0 0 0 0 0 0 0.37 0.38 0.53 0.73
DII 0.2 0.67 0.68 0.41 0.88 0.92 0.83 0.83 0.82 0.85
Public 29.46 30.61 30.61 30.87 30.41 30.36 30.08 30.08 30.17 30.33
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 75.08 to 68.44days.
  • Company is almost debt free.

Cons

  • Stock is trading at 4.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Jagsonpal Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!